This study is an epidemiological non-interventional trial that aims to evaluate standard daily practice in managing patients with arterial hypertension. The trial only records real-life clinical practice with no additional diagnostic or monitoring procedures. The study is purposed to collect the following Egypt-specific epidemiology data on hypertension: demographic data, patients' characteristics, and patients' management/treatment in order to reach its rationale.
This study is aimed to evaluate response rate of the antihypertensive treatment with Thiazide Diuretics, calcium antagonist, Angiotensin Converting enzyme Inhibitor, Angiotensin II receptor blocker, and Beta Blocker in real life practice, and to collect the following Egypt-specific epidemiology data on hypertensive patients: demographic data, patents characteristics, and patients' management/treatment. Approximately 300 sites will be participating (1 investigator per site; 300 investigators). Patients that are to be enrolled will either be newly diagnosed with hypertension, or on current antihypertensive treatment, compiling a total of 3000 patients (21 years, or older). The study will be conducted in two sequential phases; the first phase will include 150 sites from Cairo, Giza and Alexandria aiming to reach 1500 patients followed by a second phase which will include 150 sites from Delta and Upper Egypt aiming to reach 1500 patients. Epidemiological data collection will take place at a single visit and Laboratory Investigations will be requested in the first visit. Patients will be followed for 3 visits with the investigator. The investigator will complete a Patient Record Form (PRF) with the patient's data: demographics, history, current antihypertensive drug treatment/treatment changes, results of physical examination, blood pressure (SBP/DBP), heart rate.
Study Type
OBSERVATIONAL
Enrollment
1,500
Research Site
Egypt, Cairo Governorate, Egypt
To insert number of hypertensive patients with SBP that are reaching treatment goals
To insert number of patients with Systolic Blood pressure reaching treatment goals according to the ESC 2013 criteria (Systolic blood pressure \<140 mmHg\* in patients) after being treated with anti-hypertensive medication/s for at least 3 months.
Time frame: 12 weeks +- 2
Insert number of patients on antihypertensive pharmacological treatment reaching the DBP goals
Inserting number of SBP patients on antihypertensive treatment reaching the DBP goals according to the Europian Society of Cardiology (ESC) 2013 guidelines.
Time frame: 12 +- 2 weeks
Insert number of patients on antihypertensive pharmacological treatment reaching SBP goals
Inserting number of patients on antihypertensive treatment reaching combined SBP \&DBP treatment goals according to Europian Society of Cardiology (ESC) 2013 guidelines.
Time frame: 12 +- 2 weeks
Insert epidemiological information on antihypertensive patients in study
* Documenting epidemiological data from the Hypertensive patients during the visit via the investigator asking them and documenting it (Age) * Documenting any associated major cardiovascular co-morbid diseases by the investigator asking the patient or checking patient history then writing it down in Case Report Form (CRF).
Time frame: 12 +- 2 weeks
Insert treatment & managing plan of antihypertensive pharmacological treatment
* Investigator is to document the treatment/management with any changes in it chosen for the patient. * to document tolerability via questionnaire.
Time frame: 12 +- 2 weeks
Insert number of patients on antihypertensive pharmacological treatment reaching DBP goals
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Inserting number of patients on antihypertensive treatment reaching combined SBP \&DBP treatment goals according to Europian Society of Cardiology (ESC) 2013 guidelines
Time frame: 12+- 2 weeks
Insert epidemiological information on antihypertensive patients in study
* Documenting epidemiological data from the Hypertensive patients during the visit via the investigator asking them and documenting it (Weight) * Documenting any associated major cardiovascular co-morbid diseases by the investigator asking the patient or checking patient history then writing it down in Case Report Form (CRF).
Time frame: 12 +- 2 weeks
Insert epidemiological information on antihypertensive patients in study
* Documenting epidemiological data from the Hypertensive patients during the visit via the investigator asking them and documenting it (gender) * Documenting any associated major cardiovascular co-morbid diseases by the investigator asking the patient or checking patient history then writing it down in Case Report Form (CRF).
Time frame: 12 +- 2 weeks
Insert treatment & managing plan of antihypertensive pharmacological treatment
* Investigator is to document the treatment/management with any changes in it chosen for the patient. * to document stability of the patient in the Case report form (CRF).
Time frame: 12 +- 2 weeks